Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”On the first day of 2026, I’m delighted to share one of my favourite pieces of work—published today in The Lancet Haematology and featured on the cover.
This Viewpoint introduces a practical decision matrix to help prioritise novel therapies for thalassemia—including disease-modifying and gene therapies—based on need, benefit, and risk, particularly in settings where access remains limited.
It also proposes realistic alternatives when standard options are not available.
The work builds on Thalassaemia International Federation guidelines, the best available trial and real-world evidence, and expert consensus from a truly global group of haematologists, transplant physicians, patient representatives, translational scientists, and trialists—bringing together 200+ years of collective clinical experience across Asia, the Middle East, Europe, and North America.
Grateful to an exceptional group of co-authors and hopeful this framework helps support more equitable, evidence-based care for patients worldwide.”
Read the full article in The Lancet Hematology.
Article: Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
Authors: Khaled Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe